**INTRODUCTION:** To demonstrate the safety of multiple doses of DWP-450, a 900kDA botulinum toxin type A for the treatment of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adult subjects.

**DESIGN:** EV006 was a multicenter, open label, repeat dose, long term exposure, year long, Phase II safety study.

**METHODS:** 570 enrolled study subjects were at least 18 years of age and had moderate (GLS=2) to severe (GLS=3) glabellar lines at maximum frown, on the 4-point photonumeric Glabellar Line Scale (GLS, 0=no lines, 1=mild, 2=moderate, 3=severe).

The primary objectives were safety related, using a broad range of measures. The primary safety analysis was the proportion of subjects with at least one adverse event.

Efficacy was evaluated by Investigator and subject, and included assessment of glabellar lines at maximum frown and at rest on the 4-point GLS.

On Day 0, eligible subjects were administered a single treatment of DWP-450 (total of 20 U, administered as 4 U/ 0.1 mL injected into each of 5 sites in the glabella).

On and after Day 90, subjects were eligible for a repeat treatment if their GLS score returned to ≥2 at maximum frown, as assessed by the Investigator.

**RESULTS:** The 570 subjects had a mean age of 50.8 years; 8.9% (51/570) were 65 years of age or older. Most (510/570, 89.5%) were female.

570 subjects received a median total dose of 60 U -- i.e. 3 treatments.

235 subjects (235/570, 41.2%) experienced a total of 475 AEs (Adverse Event). Sixty-one subjects (61/570, 10.7%) experienced a total of 91 AEs (91/475 events, 19.2%) assessed by the Investigator as study drug related.

Seven subjects (7/570, 1.2%) experienced 8 SAEs (Serious Adverse Event). No SAE was assessed as study drug related.

There were 6 related events of eyelid ptosis (6/570, 1.1%).

There were no cases of antibotulinum toxin antibody seroconversion during the trial.

At Day 30 after initial treatment, by Investigator assessment, 96.9% (538/566) of subjects had a ≥1 point improvement on the GLS.

**CONCLUSION:** DWP-450, a purified botulinum toxin type A, used for the treatment of moderate-to-severe glabellar lines was studied in a 570 subject, multi-center, open label, repeat dose, long term exposure, year long Phase II safety study. Most AEs were injection site reactions of mild to moderate severity.
